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INTRODUCTION 
Attention-deficit/hyperactivity disorder (ADHD) is a com-
mon neurobehavioral disorder, affecting approximately 5% of 
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school-age children worldwide,
1 and an estimated 5.9% of chil-
dren in Korean elementary schools.
2
Treatment for ADHD aims to reduce symptoms, enhance fun-
ctionality and improve individual and family well-being.
3 Stan-
dardized stimulant pharmacotherapy for ADHD is associated 
with superior symptom reduction compared with psychother-
apy alone but up to 30% of patients may not respond or are in-
tolerant to stimulant medications.
4 Atomoxetine is a novel non-
stimulant treatment for ADHD with a different mode of action 
to other currently approved (stimulant) medications.
5 The effi-
cacy and safety of atomoxetine in treating ADHD has been de-
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or 0.2 mg/kg/day (29.4%; p=0.005). These were generally mild to moderate.
ConclusionaaAtomoxetine was found to be safe and well tolerated at all doses administered in Korean pediatric ADHD patients, and 1.2 
mg/kg/day was an efficacious dose in this population.  Psychiatry Investig 2011;8:141-148
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monstrated in numerous randomized, double-blind, placebo-
controlled trials and open-label studies in children, adolescents 
and adult patients.
4 These studies have included over 4,000 
child and adolescent patients, of whom over 1,100 have been 
followed for more than 6 months, establishing the efficacy and 
tolerability of atomoxetine in the treatment of ADHD.
4,6-14 
A dose-response relationship for atomoxetine was demon-
strated in a pivotal fixed-dose, double-blind, randomized, con-
trolled trial in the United States, in which atomoxetine 1.2 mg/
kg/day was identified as an optimal dose for most patients.
11 Al-
though the majority of studies investigating atomoxetine have 
been conducted in predominantly Caucasian populations, it has 
also been shown to be effective and well-tolerated by children 
and adolescents in Asia, including in Taiwan, China, Japan and 
Korea.
15-17 However, the dose response of atomoxetine in these 
populations has not been extensively studied. 
Atomoxetine has received approval for the treatment of chil-
dren and adolescents with ADHD from the Korean Food and 
Drug Administration but the dose response of atomoxetine in 
Korean pediatric patients has not been studied specifically. The 
primary aim of this study, therefore, was to assess the response 
to three different doses of atomoxetine in Korean pediatric out-
patients with ADHD. The safety and tolerability of atomoxetine 
at each dose were also assessed.
METHODS
Partipants
All patients enrolled in this study conducted in Korea were 
children or adolescents of Korean origin aged 6 to 18 years, 
with a diagnosis of ADHD as defined by The American Psy-
chiatric Association Diagnostic and Statistical Manual of Men-
tal Disorders, Fourth Edition, Text Revision (DSM-IV-TR) di-
agnostic criteria.
18 Patients were eligible for enrollment if they 
recorded symptom severity thresholds of 1.5 standard devia-
tions above age and gender norms (based on a large, represen-
tative sample of the North American population) on the ADHD 
Rating Scale-IV-Parent: Investigator-Administered and Scored 
(ADHDRS-IV-Parent:Inv),
19 and a Clinical Global Impressions-
ADHD-Severity (CGI-S) score ≥4 at Visits 1 and 2. Enrolled pa-
tients also had to meet all of the following criteria: did not take 
any medication for ADHD treatment at least 2 weeks prior to 
randomization and at least 1 week prior to obtaining baseline 
ADHDRS-IV-Parent:Inv and CGI-S scores; had no significant 
laboratory abnormalities or clinical conditions that would pre-
clude participation at study entry; had no impairment in intel-
ligence as assessed clinically by the investigator; and were able 
(along with parents or legal guardian) to keep appointments for 
clinic visits and all examinations as required by the protocol. In-
formed consent was obtained from all parents or legal represen-
tative, and patients where appropriate, prior to study initiation.
The study protocol was approved by the Ethical Review Board 
of each participant investigational hospital: Seoul National 
University Hospital, Soonchunhyang University Bucheon 
Hospital, Asan Medical Center, Yonsei University Severance 
Hospital, Hanyang University Medical Center, Kangbuk Sam-
sung Hospital, and Gachon University Gil Hospital in South 
Korea.
Patients were not eligible for enrollment if they had partici-
pated in a previous study of atomoxetine; had a history of bipo-
lar disorder, psychosis, autism, Asperger’s syndrome, pervasive 
developmental disorder, or conduct disorder; had a history of 
any seizure disorder, or were taking anticonvulsants for seizure 
control; were at serious risk of suicide; were likely to need psy-
chotropic medications other than the study drug, including 
Chinese medicine, herbal medicine, and/or health food sup-
plements that had central nervous system activity. Patients were 
discontinued from the study if they were significantly non-com-
pliant with the study drug (defined below), or required treat-
ment with another therapeutic agent for the treatment of ADHD 
or a psychoactive medication excluded by the study protocol. 
Study design 
This was a Phase 3b multicenter, randomized, open-label, 
parallel trial with two study periods conducted to provide ad-
ditional efficacy and safety information on the response to three 
different doses of atomoxetine within the Korean pediatric 
ADHD population. Enrolled patients were randomized to one 
of three treatment arms, with treatment given orally in two di-
vided doses, for 6 weeks. In this open-label setting, a sub-ther-
apeutic pseudo-placebo arm (Arm 1; atomoxetine 0.2 mg/kg/
day) was utilized instead of placebo for practical and ethical 
reasons. The actual doses of study treatment received by pa-
tients may have varied because of the limited capsule sizes avail-
able and variations in patients’ body weight. Patients in Arm 2 
received atomoxetine at a target dose of 0.5 mg/kg/day and pa-
tients in Arm 3 were exposed to atomoxetine in a dose escala-
tion fashion from a target of 0.5 mg/kg/day for 7 days followed 
by 0.8 mg/kg/day for 7 days, then 1.2 mg/kg/day thereafter; 
the dose is referred to as 1.2 mg/kg/day in this report for simplic-
ity. The 6-week treatment period was considered appropriate 
based on data from previous studies of atomoxetine.
Enrolled patients were randomized by a computer generat-
ed random sequence in a 1 : 1 : 1 ratio to the three treatment arms 
at Visit 2. Patients were considered significantly non-compliant 
if they missed three consecutive doses of the study medication 
or failed to take at least 80% of the prescribed doses of medica-
tion during two or more visit intervals, or if they had intention-
ally or repeatedly taken more than 120% of the prescribed dose. 
All medications other than the study drug taken during the S Cho et al. 
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study were recorded. Patients were permitted to take over the 
counter medication or prescription medications not specifi-
cally excluded from the study protocol (including aspirin, cold 
preparations, iron supplements and vitamins). This study was 
conducted in accordance with the ethical principles that have 
their origin in the Declaration of Helsinki. 
Efficacy and safety measures
The primary objective of the study was to assess the change 
in ADHD symptoms using three different doses of atomoxetine 
in the Korean pediatric ADHD population. The primary effi-
cacy measure used in this study was the ADHDRS-IV-Parent: 
Inv total scale score,
19,20 an 18-item scale corresponding with 
each of the 18 symptoms described by the DSM-IV-TR, which 
has been validated in the Korean language.
21 Each item is scor-
ed on a 0- to 3-point scale, assessing symptom severity in the 
past week. The total score was computed as the sum of the sco-
res for each item, and primary efficacy measured as change from 
baseline to last observation carried forward (LOCF) endpoint. 
Inattention and hyperactivity/impulsivity subscores were also 
computed. Secondary objectives of this study were to assess 
the efficacy of each dose in reducing the severity ADHD symp-
toms, and the safety and tolerability of atomoxetine at each dose. 
Secondary efficacy measures were the change from baseline to 
endpoint in the CGI-S rating scale and the Clinical Global Im-
pressions-ADHD-Improvement (CGI-I) score at the end of 
study (6 weeks). Safety assessments included: adverse events 
(AEs); laboratory data (chemistry, hematology, urinalysis, urine 
drug screen, thyroid function test, pregnancy test if necessary), 
completed at Visit 1 for screening purposes; vital signs [systolic 
and diastolic Blood pressure (BP), body temperature, pulse rate, 
weight and height, and body mass index], recorded at regular 
intervals; Columbia Suicide-Severity Rating Scale and the “Self-
Harm Supplement” Form, which were completed if an investiga-
tor suspected that an adverse event represented suicidal thought 
or behavior, or if a self-harm event was reported.
Statistical analyses 
Efficacy analyses were performed on an intention-to-treat 
(ITT) basis in which all randomized patients with a baseline 
and at least one post-baseline ADHDRS-IV-Parent:Inv total 
score and CGI-S score were included and subsequently analyzed 
according to their original randomly assigned treatment group. 
Adverse event analyses were conducted on all data from all pa-
tients receiving at least one dose of the study drug and grouped 
by the actual maximum dose the patient received over all visits 
(not the assigned dose as per ITT). Patients were thus allocat-
ed to one of three groups based on the actual dose received (re-
ferred to as Dosage Groups): 1) 0.01-0.35 mg/kg/day, 2) 0.36-
0.85 mg/kg/day, 3) >0.85 mg/kg/day. These groups overlapped 
almost entirely with the treatment arms based on target doses 
used in the ITT analyses. The percentages of randomized pa-
tients who completed or discontinued Study Period II were 
summarized overall and by treatment arm, and possible treat-
ment differences were assessed using Fisher’s exact test. Patient 
discontinuation in Study Period I was summarized by percent-
ages and counts. Patient baseline characteristics (demograph-
ics, ADHD characteristics, historical illness and pre-existing con-
ditions) were summarized with descriptive statistics. The percen-
tage of patients with significant non-compliance, and use of 
concomitant medication was summarized by visit and over-
all, and by treatment arm. Unless otherwise specified, all for-
mal tests were conducted at a two-sided alpha level of 0.05.
Primary efficacy analysis
The primary summary statistic used to assess dose response 
was the least squares mean overall change from baseline to end-
point [6 weeks (LOCF)] in ADHDRS-IV-Parent:Inv total score 
for each treatment arm, calculated (with 95% CI) using an anal-
ysis of covariance (ANCOVA) model with a LOCF approach to 
impute missing data. This model included pre-specified covari-
ates of baseline ADHDRS-IV-Parent:Inv total score, treatment 
arm and investigator. The primary efficacy analysis was also re-
peated using a longitudinal/mixed effects model with repeated 
measures (MMRM) approach in a sensitivity framework. 
Secondary efficacy analyses 
The secondary summary statistics were the change from 
baseline to endpoint in CGI-S and endpoint measure of CGI-
I for each treatment arm. Longitudinal profiles of change from 
baseline score were generated using a MMRM approach for 
CGI-S and CGI-I data with pre-specified fixed effect covariates 
of baseline CGI-S score, treatment arm, visit, investigator and 
treatment arm-by-visit interaction, with an unstructured cova-
riance matrix. Contrasts between treatment arms were made at 
Visit 5. The longitudinal analyses of CGI-S and CGI-I scores 
using MMRM were repeated using ANCOVA and LOCF ap-
proaches, which were compared with the protocol-specified 
secondary analyses as a sensitivity framework. Contrasts be-
tween treatment arms were made at 42 days, and were also com-
pared with the protocol-specified secondary analyses as a sensi-
tivity framework.
Additional efficacy analyses
To further support the specified primary and secondary as-
sessments of the dose response, monotonic dose response (st-
rictly increasing response with increasing dose) was statistical-
ly tested using a 1-sided Williams test with a 0.025 significance 
level.
22 144  Psychiatry Investig 2011;8:141-148
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Determination of sample size
A sample size of 150 patients, allocated in a 1 : 1 : 1 ratio to the 
three treatment arms, was chosen on a pragmatic basis that this 
would be a sufficient number of patients to adequately provide 
a meaningful dose response plot as well as useful safety and tol-
erability profiles. 
RESULTS
Patient disposition 
The study cohort disposition is summarized in Figure 1. Safe-
ty analyses were conducted on the as-treated population (n= 
153) according to the actual atomoxetine dose taken during the 
study. Consequently, the safety analysis assessed 51 patients in 
Dosage Group 1, 54 patients in Dosage Group 2, and 48 patients 
in Dosage Group 3. The majority of patients in all three arms 
were compliant with treatment overall [2 patients (3.9%) in Arms 
1 and 3, and 3 patients in Arm 2 (5.9%) were deemed signifi-
cantly non-compliant]. The most common previous treatment 
class (25.5% overall: Arm 1=23.5%, Arm 2=27.5%, Arm 3= 
25.5%) was centrally acting sympathomimetics (methylpheni-
date formulations). The most common post-randomization 
concomitant medication class (3.9% overall: Arm 1=3.9%, Arm 
2=5.9%, Arm 3=2.0%) was sympathomimetics (pseudoephed-
rine and phenylephrine).
Baseline demographics 
Table 1 summarizes the baseline demographics and disease 
characteristics for all randomized patients.
Primary efficacy analysis: ADHDRS-IV-Parent:Inv 
Figure 2 provides a graphical representation of the primary 
efficacy analysis results, demonstrating the evident monoton-
ic ordering of dose response. The least-squares mean changes 
from baseline to endpoint ADHDRS-IV-Parent:Inv total sc-
ores were -9.6, -12.3, and -14.5 with atomoxetine 0.2, 0.5 and 
1.2 mg/kg/day, respectively (p=0.024 - F-test). 
The ANCOVA model for ADHDRS-IV-Parent:Inv total 
score demonstrated a significantly greater improvement in 
mean change from baseline to endpoint for atomoxetine 1.2 
mg/kg/day in a pairwise comparison with atomoxetine 0.2 
mg/kg/day (p=0.006), and the mean difference of 4.96 after 6 
weeks between these treatment arms was considered clinically 
significant. Pairwise comparisons for mean change from base-
line to endpoint ADHDRS-IV-Parent: Inv score showed a mean 
difference of 2.21 (p=0.20) between atomoxetine 1.2 and 0.5 mg/
kg/day, and 2.76 (p=0.12) for 0.5 and 0.2 mg/kg/day.
Secondary efficacy analyses-mean change 
from baseline CGI-S score 
Overall, patients were “moderately” ill at endpoint (mean 
CGI-S score: 4.02), compared with “markedly” ill at baseline 
(mean CGI-S score: 5.27). Table 2 illustrates the mean CGI-S 
score by visit for all treatment arms. Atomoxetine 1.2 mg/kg/
day was associated with greater improvement from baseline to 
endpoint CGI-S score compared with atomoxetine 0.2 mg/kg/
day at 6 weeks (-1.54 versus -0.98; p=0.011). 
174 patients entered
18 screen failures
Arm 1
51 patients treated
Arm 1
10 patents discontinued
·Parent/caregiver decision  7
·Adverse event                      2
·Protocol violation               1
Arm 2
5 patents discontinued
·Adverse event                      3
·Parent/caregiver decision  2
Arm 3
5 patents discontinued
·Adverse event                      3
·Parent/caregiver decision  2
Arm 2
51 patients treated
Arm 3
51 patients treated
153 patients randomized
Arm 1
41 patients completed treatment
Arm 2
46 patients completed treatment
Arm 3
46 patients completed treatment
Figure 1. Patient disposition.S Cho et al. 
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Secondary efficacy analyses-mean CGI-I score 
Table 2 illustrates the mean CGI-I score by visit for all treat-
ment arms. Patients receiving atomoxetine 1.2 mg/kg/day sh-
owed greater improvement in mean CGI-I score than patients 
receiving atomoxetine 0.2 mg/kg/day at 6 weeks (mean CGI-
I score: 2.80 versus 3.29; p=0.0025). 
Additional analyses
The null hypothesis addressed by the Williams test maintains 
that the mean response for all dose groups is equal while the al-
ternative hypothesis maintains that a monotone dose-response 
relationship exists. The result comparing the 1.2 and 0.2 mg/
kg/day treatment arms (p=0.016) suggests that there is strong 
evidence to reject the null hypothesis in favor of a monotone 
dose-response relationship.
Safety and tolerability 
There were no deaths reported in this study. Two patients 
[one patient in each of Dosage Group 2 (0.36-0.85 mg/kg/day) 
and 3 (>0.85 mg/kg/day)] experienced serious AEs that were 
considered by the investigator to be unrelated to the study drug. 
Eight patients discontinued due to AEs: two patients in Arm 1, 
three patients in Arm 2, and three patients in Arm 3 (Figure 1).
The most frequently reported AEs (occurring in ≥5% of pa-
tients) are shown in Table 3. The majority of these events were 
mild or moderate, and no events related to suicide ideation or 
self-harm were reported. More patients receiving atomoxetine 
at approximately 1.2 mg/kg/day (Dosage Group 3) reported ≥1 
treatment-emergent adverse event/s (58.3%) compared with 0.5 
(Dosage Group 2; 40.7%; p=0.11) or 0.2 mg/kg/day (Dosage 
Group 1; 29.4%; p=0.005).
BP fluctuations were observed for some patients at the begin-
ning of the study, although these were not unidirectional and 
tended to normalize during the study period. No clinically sig-
nificant mean changes in systolic or diastolic BP from baseline 
to endpoint were observed between treatment groups. Longi-
tudinal changes in the systolic and diastolic BP of patients in 
Arm 3 (1.2 mg/kg/day target dose), and a summary of the mean 
Table 1. Patient baseline demographics and disease characteristics 
Characteristic Arm 1 (N=51) Arm 2 (N=51) Arm 3 (N=51) Total (N=153)
Mean age (years) 9.80 9.87 9.65 9.78
Age 6-12 years, N (%) 38 (74.50) 44 (86.30) 44 (86.30) 126 (82.40)
Mean weight (kg) 35.67 35.54 35.48 35.56
Male, N (%) 47 (92.20) 41 (80.40) 40 (78.40) 128 (83.70)
Female, N (%)  4 (7.80) 10 (19.60) 11 (21.60) 025 (16.30)
Mean CGI-S score 5.35 5.31 5.16 5.27
Mean ADHDRS-IV-Parent:Inv
Total score 39.08 37.67 36.16 37.63
Inattention subscale score 21.57 21.06 20.20 20.94
Hyperactive/Impulsive subscale score 17.51 16.61 15.96 16.69
CGI-S: Clinical Global Impressions-ADHD-Severity, ADHDRS-IV-Parent:Inv: Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-
Parent: Investigator-Administered and Scored 
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Primary Efficacy Analysis ADHDRS-IV-Parent:Inv-ddddChange from 
Baseline to LOCF Endpoint: Intention to Treat Population
Arm 1 
(N=51)
Arm 2 
(N=51)
Arm 3 
(N=51)
p-value
Baseline 38.76                                             37.67.   35.92   0.0397
LOCF endpoint  Mean                                                                                                                                            28.80 25.78.   22.16 0.024
Change      
  Adjusted LS Mean            
-9.55 -12.310 -14.51 0.024
Adjusted 95%  
  Lower CL      
-12.03 -14.760 -16.99
Adjusted 95%  
  Upper CL       
-7.07 -9.85 -12.04
Figure 2. Graphical representation of the monotonic order of dose 
response to three doses of atomoxetine. ADHDRS-IV-Parent:Inv - 
Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent: In-
vestigator-Administered and Scored. LOCF: last observation carried 
forward, LS: least squares, CL: confidence limits146  Psychiatry Investig 2011;8:141-148
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change in vital signs measurements for all treatment arms from 
baseline to endpoint are shown in Figure 3.
DISCUSSION 
This is the first study evaluating the dose response of ato-
moxetine for treating ADHD in a Korean population. A mono-
tonic ordering of dose response for atomoxetine prescribed at 
0.2 mg/kg/day, 0.5 mg/kg/day, and 1.2 mg/kg/day in the im-
provement of ADHD symptoms in Korean children and ad-
olescents following 6 weeks of treatment was demonstrated. 
The additional sensitivity analyses provided strong supportive 
evidence of the monotonic dose-response relationship observed 
in the primary efficacy analysis. Furthermore, atomoxetine 1.2 
mg/kg/day showed clinically meaningful and statistically sig-
nificant improvements in ADHD symptoms compared with 
atomoxetine 0.2 mg/kg/day. Most treatment-emergent AEs 
observed with all three doses of atomoxetine were of mild or 
moderate severity and no unexpected safety findings were re-
ported.
The monotonic ordering of dose response observed here 
strongly reflects observations in other studies conducted world-
wide. In the pivotal fixed-dose, 8-week, placebo-controlled 
study of atomoxetine in the treatment of ADHD in children 
and adolescents in the United States, atomoxetine 1.2 mg/kg/
day demonstrated a mean change from baseline to endpoint 
ADHDRS-IV-Parent:Inv total score of -13.6 (SD 14.0).
11,23 In 
this study, atomoxetine 1.2 mg/kg/day produced a similar 
mean change from baseline to endpoint ADHDRS-IV-Parent: 
Inv total score of -14.5 (SD 9.71), providing evidence that ato-
moxetine 1.2 mg/kg/day is as effective in Korean pediatric and 
adolescent patients as it is in patients from the United States. 
These data also suggest that atomoxetine 1.2 mg/kg/day and 0.5 
mg/kg/day provide clinically superior efficacy compared with 
0.2 mg/kg/day in the Korean population. However, the study 
was not principally designed to make pairwise comparisons be-
tween treatment arms and it is therefore difficult to draw fur-
ther conclusions from these data. The data presented in this 
study are consistent with observations of an atomoxetine dose 
response in Caucasian pediatric ADHD populations and also 
support the limited data available from studies in Korea, Chi-
na, Taiwan and Japan showing the efficacy of atomoxetine in 
Table 3. Summary of treatment-emergent adverse events in Dosage Group (safety analysis population)
Event
1
(0.01-0.35)* (N=51)
2
(0.36-0.85)* (N=54)
3
(>0.85)* (N=48)
≥1 TEAE, N (%) 15 (29.41) 22 (40.74) 28 (58.33)
Mild 13 (25.49) 19 (35.19) 23 (47.92)
Moderate 1 (1.96) 2 (3.70) 05 (10.42)
Severe 1 (1.96) 1 (1.85) 0 (0.00)
TEAEs (≥ 5%), N (%)
Upper abdominal pain 0 (0.00) 5 (9.26) 04 (8.33)0
Anorexia 2 (3.92) 2 (3.70) 06 (12.50)
Decreased appetite 1 (1.96) 4 (7.41) 06 (12.50)
Dizziness 1 (1.96) 3 (5.56) 0 (0.00)
Irritability 2 (3.92) 2 (3.70) 4 (8.33)
Nasopharyngitis 3 (5.88) 4 (7.41) 2 (4.17)
Nausea 2 (3.92) 3 (5.56) 2 (4.17)
Sleep disturbance 4 (7.84) 0 (0.00) 1 (2.08)
Somnolence 0 (0.00) 1 (1.85) 4 (8.33)
*mg/kg/day. TEAE: treatment-emergent adverse event
Table 2. Mean overall CGI-S† and CGI-I‡ scores for each treatment arm by visit 
Visit
Arm 1 (N=51) Arm 2 (N=51) Arm 3 (N=51)
CGI-S CGI-I CGI-S CGI-I CGI-S CGI-I
3 5.11 3.57 4.78 3.22 4.86 3.54
4 4.62 3.25 4.41 3.20 4.24 2.98
5 4.31 3.24 4.01 3.09 3.60     2.77**
LOCF endpoint 4.37 3.29 4.09 3.16   3.62* 2.80
*p=0.0011 versus Arm 1, **p=0.0025 versus Arm 1, p=0.0452 versus Arm 2. CGI-S: Clinical Global Impressions-ADHD-Severity, CGI-I: 
Clinical Global Impressions-ADHD-Improvement. LOCF: last observation carried forwardS Cho et al. 
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Asian pediatric ADHD patients.
15-17 
All three doses of atomoxetine evaluated in this study 
proved to be safe and well-tolerated by Korean pediatric pa-
tients. Adverse event rates were generally dose-dependent; 
atomoxetine >0.85 mg/kg/day was associated with higher 
rates of AEs than 0.36-0.85 mg and 0.01-0.35 mg/kg/day, but 
most treatment-related AEs were mild to moderate and are 
consistent with those observed in global studies.
4,7,11,13,23-25 
While it has been suggested that the Korean population may 
experience AEs at relatively lower doses of psychotropic med-
ications,
26 the incidence of AEs reported here are lower than 
those reported in other studies of atomoxetine (0.8-1.8 mg/
kg/day) in Asian and Hispanic pediatric populations.
15,17 Im-
portantly, the high completion rate of 86.9% observed in this 
study emphasizes the favorable tolerability of atomoxetine in 
Korean pediatric patients. BP fluctuations were observed early 
in this study, although BP normalized within the study peri-
od in most patients and there was no significant increase in 
BP reported between treatment arms. This is consistent with 
findings in studies of Caucasian and non-Caucasian pediatric 
patients
7,11-13,15,17,24,26 and may be expected given the increases 
in noradrenergic tone observed with atomoxetine.
27
The interpretation of these data is limited by several factors. 
Most importantly, the study was not designed principally to 
make pairwise comparisons between treatment arms. It is also 
possible that the open-label study design may have introduced 
investigator or patient and parent bias in favor of all doses, 
which could have influenced outcomes. Additionally, the study 
assessed only core ADHD symptoms using the ADHDRS-IV-
Parent:Inv, CGI-S and CGI-I scales; the data do not describe 
the severity or prevalence of ADHD comorbidities in this pop-
ulation, which may have also influenced study assessments. 
Furthermore, the relatively short 6-week study period means 
that long term safety issues cannot be addressed.
Overall, atomoxetine was found to be safe and well tolerated 
at all doses administered in the Korean patients participating 
in the study, and 1.2 mg/kg/day was found to be an efficacious 
dose in this patient population.
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Figure 3. Longitudinal change in systolic (A) and diastolic (B) blood pressure (mmHg) in patients receiving atomoxetine at a target dose of 1.2 
mg/kg/day (Arm 3) and summary of mean change in vital signs from baseline to endpoint in all treatment arms. 
Summary of mean changes in vital sign measurements from baseline to endpoint (ITT population)
Arm 1 (N=51) Arm 2 (N=51) Arm 3 (N=51)
Systolic BP* (SD†) 0.98 (16.5) 2.35 (12.1) 1.72 (13.9)
[95% CI‡] [-4.05, 6.0] [-1.25, 5.95] [-2.42, 5.85]
Diastolic BP (SD) 0.16 (13.2) 3.65 (12.1) 2.17 (13.2)
[95% CI] [-3.85, 4.17] [0.07, 7.23] [-1.75, 6.09]
Heart rate, bpm (SD) 2.59 (13.0) 5.24 (13.6) 4.98 (14.6)
[95% CI] [-1.37, 6.56] [1.19, 9.28] [0.63, 9.33]
Weight, kg (SD) 0.37 (1.5)0 -0.08 (1.2)0. -0.15 (1.1)0.
[95% CI] [-0.09, 0.83] [-0.42, 0.26] [-0.47, 0.18]
*Blood pressure (mmHg), †Standard deviation, ‡95% confidence interval. ITT: intention-to-treat
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